CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

This is a Korean post-marketing surveillance study that is monitoring the real-world safety and use of capivasertib — an AKT inhibitor drug used for certain breast cancers — in patients who are receiving it as part of their approved treatment in South Korea. **You may be eligible if...** - You are being prescribed capivasertib in South Korea for an approved indication (as per its label) - You have provided signed informed consent (or a legal representative has done so on your behalf) **You may NOT be eligible if...** - You are using capivasertib for a reason not listed on its approved South Korean label (off-label use) - You are already participating in another interventional clinical trial while on capivasertib Talk to your doctor to see if this trial is right for you.